Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER_GOV 2INDUSTRY 2OTHER 1

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Gynecologic 5Breast 3Thoracic 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Ovarian Neoplasms 4Recurrence 2Neoplasms 2Hypersensitivity 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Poly(ADP-ribose) Polymerase Inhibitors × Gynecologic × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03951415 2021-04-01

DOMEC

Leiden University Medical Center

Phase 2 Unknown
55 enrolled
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
41 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
43 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡